glp-1 weight regain after stopping receptor agonists | Gustavo Monnerat posted on the topic The truth about GLP1 weight

A new prior authorization is generally not needed for: Regular monthly refills An increase in dose A decrease in dose Your provider must still send a new prescription when your dose changes

It is currently undergoing clinical trials

1 Based on actual data from approximately 17,000 patients at week 17 of the Kaiser Permanente Northern Californias 82-week long Medical Weight Management program

In small proof-of-concept phase 2 randomized controlled trials (RCTs) in patients with biopsy-confirmed MASH, liraglutide at 1.8 mg/day for 48 weeks (201), semaglutide at 0.4 mg/day for 72 weeks (202), and tirzepatide at 15 mg/week for 52 weeks (203) have been reported to achieve placebo-corrected percentages of participants meeting the criteria for resolution of MASH without worsening fibrosis by 30% (P = 0.019), 42% (P 10%) may lead to diabetes remission (237)